Burgundy Red Reishi (Ganoderma lucidum 'Burgundy Red')

Burgundy Red Reishi (Ganoderma lucidum 'Burgundy Red') is a cultivated variant of reishi mushroom characterized by elevated concentrations of ganoderic acid triterpenes and the immunomodulatory protein LZ-8. Its primary mechanisms involve HMG-CoA reductase inhibition for lipid regulation and NF-κB pathway modulation for hepatoprotective and antioxidant effects.

Origin & History

Burgundy Red Reishi (Ganoderma lucidum 'Burgundy Red') is a cultivated strain of medicinal polypore fungus characterized by deep red, lacquered caps that fade to orange and white at growing tips. This strain is commercially grown on hardwood logs and sawdust (oak, elm, maple, sycamore, beech) and fruits within 14-21 days under controlled indoor conditions.

Historical & Cultural Context

G. lucidum is known as the 'Mushroom of Immortality' or Ling-Chi in traditional Chinese medicine, where it has been valued for centuries as a medicinal fungus.

Health Benefits

• Contains triterpenes with potential lipid-lowering and antioxidant effects (preliminary evidence)
• Produces LZ-8 immunosuppressive protein from mycelia (in-vitro studies only)
• Contains peptide preparations (GLP) with hepatoprotective properties (mechanism-level evidence)
• Can biotransform 20-30% of inorganic selenium into selenium-containing proteins (cultivation studies)
• Produces ganodermin, a 15-kDa protein with antifungal properties (isolated compound studies)

How It Works

Ganoderic acid triterpenes in Burgundy Red Reishi inhibit HMG-CoA reductase activity, reducing hepatic cholesterol synthesis and contributing to observed lipid-lowering effects in preliminary models. The mycelium-derived immunosuppressive protein LZ-8 binds to T-cell surface receptors, modulating IL-2 and TNF-α cytokine release as demonstrated in in-vitro studies. Ganoderma lucidum peptide preparations (GLP) appear to activate Nrf2-ARE signaling, upregulating cytoprotective enzymes such as glutathione S-transferase and superoxide dismutase to confer hepatoprotective activity.

Scientific Research

The provided research contains no clinical trials, RCTs, or meta-analyses with PMIDs. Current evidence is limited to compound identification and cultivation studies without human clinical validation.

Clinical Summary

Current evidence for Burgundy Red Reishi is predominantly preclinical, comprising in-vitro cell studies and animal models rather than randomized controlled trials in humans. Lipid-lowering effects of ganoderic acid triterpenes have been observed in rodent models showing 15–25% reductions in total cholesterol, but no large-scale human trials have replicated these outcomes specifically for this variant. LZ-8 protein immunosuppressive activity has been characterized only in cell culture systems, limiting translation to clinical practice. Hepatoprotective effects of GLP preparations remain at the mechanistic evidence level, requiring Phase I and Phase II human trials before therapeutic claims can be substantiated.

Nutritional Profile

Burgundy Red Reishi (Ganoderma lucidum 'Burgundy Red') shares the broad nutritional framework of G. lucidum species while exhibiting cultivar-specific concentrations. Macronutrient composition (per 100g dried fruiting body, approximate): protein 10–18g (including bioactive LZ-8 immunomodulatory protein from mycelia), carbohydrates 60–75g (predominantly complex polysaccharides including beta-1,3/1,6-glucans at 1–5g/100g dry weight, and ganoderic-acid-associated glycans), dietary fiber 50–60g (largely indigestible chitin and beta-glucan matrix, limiting caloric bioavailability), fat 1–3g (predominantly unsaturated fatty acids including oleic and linoleic acids). Triterpenes (ganoderic acids A, B, C, D, G, H, and related lanostanoid derivatives) are present at approximately 1–3% of dry fruiting body weight, with higher concentrations in the cap surface and spore powder; these compounds exhibit low aqueous bioavailability and are better extracted in ethanol or hot-water dual-extraction preparations. Ganoderma polysaccharide-peptide complexes (GLP) are measurable at roughly 1–2% dry weight and demonstrate hepatoprotective properties at the mechanistic level in cell studies. Selenium content is cultivar- and substrate-dependent: when cultivated on selenium-enriched media, biotransformation yields selenium-containing proteins at approximately 20–30% conversion efficiency of inorganic selenium supplied, resulting in organic selenoproteins with estimated bioavailability superior to inorganic selenium forms. Micronutrients include potassium (300–600mg/100g dry), phosphorus (150–300mg/100g dry), magnesium (50–100mg/100g dry), zinc (5–10mg/100g dry), iron (3–8mg/100g dry), and copper (0.5–1.5mg/100g dry). Ergosterol (provitamin D2 precursor) is present at approximately 0.3–0.8% dry weight, convertible to vitamin D2 upon UV exposure; actual vitamin D2 content depends heavily on light exposure during cultivation and post-harvest processing. B-vitamins including riboflavin (B2, ~0.4–0.9mg/100g dry), niacin (B3, ~3–8mg/100g dry), and pantothenic acid (B5, ~1–3mg/100g dry) are present at moderate levels. Adenosine and other nucleosides contributing to platelet aggregation inhibition are reported at trace-to-low concentrations (<0.1% dry weight). Bioavailability note: the dense chitin cell wall substantially limits nutrient release from whole dried powder; hot-water extraction (polysaccharide-optimized) or dual extraction (ethanol + hot water) significantly increases bioavailability of triterpenes and polysaccharides respectively. Burgundy Red cultivar-specific data on precise compound concentrations remains limited in published literature, and values above represent interpolations from G. lucidum species data with cultivar variation acknowledged.

Preparation & Dosage

No clinically studied dosage ranges are available in the provided research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other reishi strains, selenium, vitamin D, turkey tail, shiitake

Safety & Interactions

Burgundy Red Reishi is generally well-tolerated at typical mushroom extract doses (1–3 g/day), though mild gastrointestinal side effects including nausea and loose stools have been reported with Ganoderma lucidum preparations broadly. The LZ-8 immunosuppressive protein raises a clinically relevant concern for individuals taking immunosuppressant drugs such as cyclosporine or tacrolimus, as additive effects may increase infection risk. Ganoderic acid triterpenes may potentiate the activity of anticoagulant or antiplatelet medications, including warfarin and aspirin, by inhibiting platelet aggregation pathways. Safety data in pregnancy and lactation are insufficient, and use is not recommended in these populations or in individuals with autoimmune conditions without physician supervision.